JP2020510661A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510661A5
JP2020510661A5 JP2019547093A JP2019547093A JP2020510661A5 JP 2020510661 A5 JP2020510661 A5 JP 2020510661A5 JP 2019547093 A JP2019547093 A JP 2019547093A JP 2019547093 A JP2019547093 A JP 2019547093A JP 2020510661 A5 JP2020510661 A5 JP 2020510661A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
xrpd
anhydrous
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019547093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510661A (ja
JP7634934B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/020968 external-priority patent/WO2018165048A1/en
Publication of JP2020510661A publication Critical patent/JP2020510661A/ja
Publication of JP2020510661A5 publication Critical patent/JP2020510661A5/ja
Priority to JP2023007546A priority Critical patent/JP2023061946A/ja
Application granted granted Critical
Publication of JP7634934B2 publication Critical patent/JP7634934B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019547093A 2017-03-06 2018-03-05 β-ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用 Active JP7634934B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023007546A JP2023061946A (ja) 2017-03-06 2023-01-20 β-ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762467752P 2017-03-06 2017-03-06
US201762467750P 2017-03-06 2017-03-06
US62/467,752 2017-03-06
US62/467,750 2017-03-06
US201762564990P 2017-09-28 2017-09-28
US201762564989P 2017-09-28 2017-09-28
US62/564,990 2017-09-28
US62/564,989 2017-09-28
PCT/US2018/020968 WO2018165048A1 (en) 2017-03-06 2018-03-05 Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023007546A Division JP2023061946A (ja) 2017-03-06 2023-01-20 β-ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用

Publications (3)

Publication Number Publication Date
JP2020510661A JP2020510661A (ja) 2020-04-09
JP2020510661A5 true JP2020510661A5 (https=) 2021-04-08
JP7634934B2 JP7634934B2 (ja) 2025-02-25

Family

ID=63448038

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019547093A Active JP7634934B2 (ja) 2017-03-06 2018-03-05 β-ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用
JP2023007546A Pending JP2023061946A (ja) 2017-03-06 2023-01-20 β-ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023007546A Pending JP2023061946A (ja) 2017-03-06 2023-01-20 β-ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用

Country Status (16)

Country Link
US (4) US11091505B2 (https=)
EP (1) EP3592362B1 (https=)
JP (2) JP7634934B2 (https=)
KR (1) KR102603489B1 (https=)
CN (2) CN110678186A (https=)
AU (1) AU2018230991B2 (https=)
CA (1) CA3055253A1 (https=)
ES (1) ES3015371T3 (https=)
HR (1) HRP20250459T1 (https=)
IL (2) IL268981B2 (https=)
MA (1) MA47743A (https=)
MY (1) MY196966A (https=)
PH (1) PH12019502037B1 (https=)
PL (1) PL3592362T3 (https=)
SG (1) SG11201908181XA (https=)
WO (1) WO2018165048A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013355110B2 (en) 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
KR102603489B1 (ko) 2017-03-06 2023-11-16 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3849562B1 (en) * 2018-09-12 2024-06-26 Venatorx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
BR112021010095A2 (pt) 2018-11-29 2021-09-28 VenatoRx Pharmaceuticals, Inc. Composições de combinação que compreendem um inibidor de beta-lactamase e usos das mesmas

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021454A (en) 1911-01-23 1912-03-26 Thomas Ernest Davis Serving-table.
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
US7875642B2 (en) 2004-01-26 2011-01-25 Merck Sharp & Dohme Corp. Crystalline forms of an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1
HRP20212002T1 (hr) 2004-03-30 2022-04-01 Millennium Pharmaceuticals, Inc. Sinteza estera i spojeva borove kiseline
CN1965838A (zh) * 2005-11-17 2007-05-23 李海超 含头孢匹胺和β-内酰胺酶抑制剂的药物组合物
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
CA2705393A1 (en) 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2009091856A2 (en) 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013014497A1 (en) 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
JP5798495B2 (ja) 2012-01-13 2015-10-21 住友理工株式会社 配線体接続構造体
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
AU2013355110B2 (en) * 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9120796B2 (en) * 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
US20150361107A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6218204B2 (ja) 2014-09-04 2017-10-25 塩野義製薬株式会社 カテコール基を有するセファロスポリン類を含有する製剤
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
MX389349B (es) 2016-06-30 2025-03-20 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos.
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
KR102603489B1 (ko) 2017-03-06 2023-11-16 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3849562B1 (en) 2018-09-12 2024-06-26 Venatorx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
BR112021010095A2 (pt) 2018-11-29 2021-09-28 VenatoRx Pharmaceuticals, Inc. Composições de combinação que compreendem um inibidor de beta-lactamase e usos das mesmas

Similar Documents

Publication Publication Date Title
JP2020510661A5 (https=)
RU2462456C2 (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JP2018115191A5 (https=)
JP2017527578A5 (https=)
JP2021063088A5 (https=)
JP2018035160A5 (https=)
JP2017531038A5 (https=)
CN109311852A (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶
CA2727378A1 (en) New co-crystal compound of rivaroxaban and malonic acid
JP2020507589A5 (https=)
JP2016522835A5 (https=)
JP2014525470A5 (https=)
JP2010514832A5 (https=)
JP2011527333A5 (https=)
JP2010521516A5 (https=)
JP2015521617A5 (https=)
RU2018114480A (ru) Соли и твердые формы монобактамного антибиотика
CN115315423A (zh) 取代芳基类化合物
JP2008513510A5 (https=)
JP2018530608A5 (https=)
JP2016510768A5 (https=)
JP2017507980A5 (https=)
JP2014517848A5 (https=)
JP2009040767A5 (https=)
JP2010500284A5 (https=)